about
sameAs
Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart diseaseEicosanoid storm in infection and inflammationEffect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure timeRole of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experienceEstrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expressionScreening and identification of dietary oils and unsaturated fatty acids in inhibiting inflammatory prostaglandin E2 signaling in fat stromal cells.Virtual screening of compounds from the patchouli oil of Pogostemon herba for COX-1 inhibition.Prostacyclin: an inflammatory paradox.Relationship between cyclooxygenase-2 inhibition and thrombogenesis.Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing?Membrane and inhibitor interactions of intracellular phospholipases A2.Inflammation and lung carcinogenesis: applying findings in prevention and treatment.Soluble factors released by Toxoplasma gondii-infected astrocytes down-modulate nitric oxide production by gamma interferon-activated microglia and prevent neuronal degeneration.An active triple-catalytic hybrid enzyme engineered by linking cyclo-oxygenase isoform-1 to prostacyclin synthase that can constantly biosynthesize prostacyclin, the vascular protector.Effects of acetaminophen on myocardial infarct size in rats.A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2.Thromboxane A2-induced arrhythmias in the anesthetized rabbit.Bioactive Lipids and Chronic Inflammation: Managing the Fire Within.Progestogens reduce thromboxane production by cultured human endothelial cells.
P2860
Q24304992-E71F4DD9-67F8-4FAF-8FDB-8965B891EAE8Q26851985-109DBCB7-F0CA-4E14-A506-4BFC9D535DC3Q28171125-97F42758-170F-4C57-9D28-5D57568116BFQ28303196-E17AB762-53D0-4240-AD8E-EAECB7CC4410Q28576245-DFA9A9BC-3D88-4D4D-9BDE-43E94971C98FQ34400103-2499FFFA-558B-4FE4-AC2F-F777757BF871Q34656034-D5BE7A3E-A020-4776-AB48-06E36C1A46D3Q35025863-683FECFB-774D-4BC1-8B42-10DE3B08E296Q35750211-C3611222-56A9-4AC8-BD7D-2F0659A7A77BQ35828904-D526EECB-7EC5-413A-9277-8BE465788059Q36945608-8D009532-EFF2-4160-A4EF-9D609186E402Q36974700-78E230B2-9949-4D76-955D-0BB6E8BC2AE8Q39741654-BFF93553-190A-493B-9C8B-4CA800137FD4Q39914094-B086F50B-8D47-43A5-B3EC-D426EAA597BCQ44739748-350F0BD4-C258-4DAB-B73C-4A593A02E0A5Q46343835-E1A31B3D-35C3-451A-A792-089A6A873CF4Q46844250-56B1EBBF-0432-4760-8776-E3565912AD0AQ49679435-1B30163B-F98E-487E-87C0-CEA568D4B730Q54429618-C7760A8E-9325-4FDA-95DF-B0502FCD57B9
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Biomedicine. Back to an aspirin a day?
@ast
Biomedicine. Back to an aspirin a day?
@en
Biomedicine. Back to an aspirin a day?
@nl
type
label
Biomedicine. Back to an aspirin a day?
@ast
Biomedicine. Back to an aspirin a day?
@en
Biomedicine. Back to an aspirin a day?
@nl
prefLabel
Biomedicine. Back to an aspirin a day?
@ast
Biomedicine. Back to an aspirin a day?
@en
Biomedicine. Back to an aspirin a day?
@nl
P356
P1433
P1476
Biomedicine. Back to an aspirin a day?
@en
P2093
John R Vane
P356
10.1126/SCIENCE.1071702
P407
P577
2002-04-19T00:00:00Z